|
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
In conclusion, NUF2 in combination with liver cirrhosis is a promising prognostic biomarker for early HCC recurrence.
|
30653265 |
2019 |
|
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results demonstrate that NUF2 plays a critical role in the regulation of HCC cell proliferation and apoptosis, indicating that NUF2 may serve as a potential molecular target for therapeutic approaches.
|
25374179 |
2014 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits.
|
28552196 |
2017 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT).
|
21738479 |
2011 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
NUF2 in combination with liver cirrhosis could significantly improve the detection of ER tumors with an AUROC of 0.82 and 0.85 in the test and validation cohort, respectively.
|
30653265 |
2019 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In the in vivo test, the tumor size was reduced obviously in the NOD/SCID mice treated with pHLIP-CDCA1-siRNA compared to the CDCA1-siRNA and the bioluminescent signal of Cy5-pHLIP-CDCA1-siRNA was focused detected in the tumor site.
|
30131247 |
2018 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Downregulation of NUF2 inhibits tumor growth and induces apoptosis by regulating lncRNA AF339813.
|
26045769 |
2015 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
SiRNA-mediated knockdown against NUF2 suppresses tumor growth and induces cell apoptosis in human glioma cells.
|
25481014 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Silencing of NUF2 inhibits tumor growth and induces apoptosis in human hepatocellular carcinomas.
|
25374179 |
2014 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
In both patients, vaccination with two epitope peptides derived from cancer/testis antigens (upregulated lung cancer 10 (URLC10) and cell division associated 1 (CDCA1)) induced specific CTLs expressing various TCRs.
|
29568993 |
2018 |
|
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The results showed that CDCA1 was highly expressed in PCa cell line and human PCa clinical samples.
|
30131247 |
2018 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The results showed that CDCA1 was highly expressed in PCa cell line and human PCa clinical samples.
|
30131247 |
2018 |
|
Carcinoma of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
In both patients, vaccination with two epitope peptides derived from cancer/testis antigens (upregulated lung cancer 10 (URLC10) and cell division associated 1 (CDCA1)) induced specific CTLs expressing various TCRs.
|
29568993 |
2018 |
|
Primary malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
In both patients, vaccination with two epitope peptides derived from cancer/testis antigens (upregulated lung cancer 10 (URLC10) and cell division associated 1 (CDCA1)) induced specific CTLs expressing various TCRs.
|
29568993 |
2018 |
|
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Cell division associated 1 (CDCA1) was screened as an oncogene that is overexpressed on several cancers, including prostate cancer.
|
28498618 |
2017 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Cell division associated 1 (CDCA1) was screened as an oncogene that is overexpressed on several cancers, including prostate cancer.
|
28498618 |
2017 |
|
Malignant neoplasm of prostate
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In univariate proportional hazards models, CEP55 (HR = 3.59, 95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95% CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95% CI: 0.21-0.93), p = 0.031 were significantly associated with the risk of PCa recurrence.
|
21917134 |
2011 |
|
Prostate carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In univariate proportional hazards models, CEP55 (HR = 3.59, 95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95% CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95% CI: 0.21-0.93), p = 0.031 were significantly associated with the risk of PCa recurrence.
|
21917134 |
2011 |
|
Malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
As a result, CDCA1 is a novel cancer-testis antigen overexpressed in LC, cholangiocellular cancer, urinary bladder cancer and renal cell cancers, and CDCA1 may therefore be an ideal TAA useful for the diagnosis and immunotherapy of these cancers.
|
18770861 |
2008 |
|
Carcinoma of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
As a result, CDCA1 is a novel cancer-testis antigen overexpressed in LC, cholangiocellular cancer, urinary bladder cancer and renal cell cancers, and CDCA1 may therefore be an ideal TAA useful for the diagnosis and immunotherapy of these cancers.
|
18770861 |
2008 |
|
Primary malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
As a result, CDCA1 is a novel cancer-testis antigen overexpressed in LC, cholangiocellular cancer, urinary bladder cancer and renal cell cancers, and CDCA1 may therefore be an ideal TAA useful for the diagnosis and immunotherapy of these cancers.
|
18770861 |
2008 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
As our data imply that human CDCA1 and KNTC2 seem to fall in the category of cancer-testis antigens, and that their simultaneous up-regulation is a frequent and important feature of cell growth/survival of lung cancer, selective suppression of CDCA1 or KNTC2 activity and/or inhibition of the CDCA1-KNTC2 complex formation could be a promising therapeutic target for treatment of lung cancers.
|
17079454 |
2006 |
|
Carcinoma of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis using lung cancer tissue microarray confirmed high levels of CDCA1 and KNTC2 proteins in the great majority of lung cancers of various histologic types.
|
17079454 |
2006 |
|
Primary malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis using lung cancer tissue microarray confirmed high levels of CDCA1 and KNTC2 proteins in the great majority of lung cancers of various histologic types.
|
17079454 |
2006 |